Loading…
Cellyan Biotechnology Co., Ltd
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in HKPD.
▼ -94.4% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 2 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2026 | 2025 |
|---|---|---|---|
| Year-end price | $0.11 | $0.82 | |
| P/S | — | 0.2x | 0.4x |
| P/B | — | 0.3x | 1.8x |
| EPS | — | -$0.00 | |
| Profit margin | — | -8.46% | -0.13% |
| ROE | — | -11.85% | -0.54% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PLSMPulsenmore Ltd. | $2.57 | — | — | — | -17.62% | $16.71M |
| LEXXLexaria Bioscience Corp. | $10.35 | — | 3.6x | — | -162.77% | $17.1M |
| CTXRCitius Pharmaceuticals, Inc. | $0.60 | — | 0.2x | — | -81.09% | $16.53M |
| PLURPluri Inc. | $1.53 |
Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over-the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services. It also offers customs clearance, drugs enlisting, warehouse, and other logistics services. In addition, it provides value-added services such as labeling, extended storage, product inspection, batch processing, and logistics support, as well as sales of health supplements and non-pharmaceutical products. The company serves e-commerce platform logistics partners, merchants, and Chinese e-commerce platforms as well as pharmaceutical distributors. The company was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and changed its name to Cellyan Biotechnology Co., Ltd in December 2025. Cellyan Biotechnology Co., Ltd was incorporated in 2023 and is based in Yau Tong, Hong Kong.
Company description provided by Yahoo Finance.
| — |
| — |
| — |
| — |
| $16.51M |
| ADILAdial Pharmaceuticals Inc | $5.60 | — | — | — | -2011.64% | $16.43M |
| BCDABioCardia, Inc. | $1.15 | — | 6.4x | — | -1803.19% | $17.41M |